Legacy cohorts and chips
FinnGen study utilizes biobank samples consisting of two entities:
Prospective samples
Prospective samples are mainly collected by hospital biobanks. A request to donate a prospective sample for biobank research can come in a variety of ways. During a hospital visit, a patient can be asked whether he or she would be interested in giving a biobank consent and donating their sample.
Legacy samples
Legacy samples are older sample cohorts that have been collected for research prior to when the Finnish Biobank Act came into effect (September 2013) and the start of FinnGen (August 2017). These cohorts have then later been transferred to various Finnish biobanks. Below you can find the legacy sample cohorts accessed in FinnGen, as well as the legacy chips used for genotyping samples from the legacy cohorts.
Legacy cohort
Biobank
Description /sample size in whole cohort
Auria legacy
Auria
Biobank samples collected in Auria in 2016 (before FinnGen started)
Auria
DIREVA is the diabetes register of the Vaasa hospital district, which is carried out through the co-operation with Lund University in Malmö, Botnia Study and University of Helsinki. 7000 participants. Blood/DNA samples available from all participants.
THL
Ongoing study since 1990 investigating diabetes risk factors To date, >15 000 participants from 1400 families. DNA available from all participants, also serum, plasma, cell and RNA samples, from subset, genotype data available from 12720, WES from 395 participants. Botnia data includes; Botnia DGI affy, Botnia T2DGo and Botnia-regeneon.
THL
Collected at the Helsinki University hospital during 2006-2008 from patients with coronary artery disease (CAD) and other related heart diseases to understand risk factors of heart diseases. DNA and genotype data available from 4890 participants.
Eastern Finland legacy
THL
KBCP (breast cancer patients, ~400), Nomod (Nordic modic project, back surgery patients, ~60), NPH (normal pressure hydrocephalus cohort, patients, relatives and contorls ~950), L-MCI (neuro/alzheimer patients, ~705)
THL
A multidisciplinary study, which focuses on identification of novel Alzheimer’s disease (AD)-associated genes and pathways using existing clinical cohorts from Eastern and Northern Finland ~1700 patients fulfilling the NINCDS-ADRDA criteria for probable AD and ~1700 cognitively healthy controls from Eastern and Northern Finland.
Eastern Finland legacy (Aneurysm)
THL
-
Eastern Finland legacy (NOMOD, IIH S100B)
THL
NOMOD (Nordic modic project, back surgery patients ~370), IIH patients (~70), S100B biomarker study (acute head injury study, n~50)
THL
A population survey study by the Finnish Institute for Health and Welfare (THL), producing up-to-date information on health, health behavior, functional capacity and well-being of adults residing in Finland. 6650 participants with DNA, serum and plasma, genotype data available from 6250 participants. NMR metabolomics from 5290.
THL
Fin-HIT is a prospective school-based cohort study including approximately 11,000 Finnish adolescents aged 9–12 years at enrolment across densely populated areas of Finland. The cohort will be followed at least for 25 years. The objectives of the study are to explore non-conventional determinants for weight and weight gain; to investigate etiology of weight-related health outcomes; and to understand underlying molecular mechanisms involved in the origin and development of obesity and related health outcomes.
THL
A nationwide registry study of idiopathic pulmonary fibrosis (IPF) patients. The aim is to monitor the prevalence, treatment, pathophysiology and prognosis IPF patients. From 2017, FinnishIPF study has collected biobank samples from 206 participants, which form the FinnIPF subcohort
THL
Cross-sectional population surveys carried out every 5 years by THL, to assess health status, risk factors of chronic diseases (e.g. CVD, diabetes, obesity, cancer) and health behavior among the working age population, in Finland. Total of 41 000 participants; Currently available: DNA 36 300, plasma/ serum 27 200 and genotype data from 31 300 participants. WES 12160, WGS 4460, NMR metabolomics 27 160. PBMC available from 2700 participants. RNA from subsets. Transcriptomics and other omics 500+500.Telomers 4070.
THL
A prospective study investigating genetic risk factors of cardiovascular diseases and utilizing genetic information in preventing diseases. Conducted in years 2015-2018 in several different areas of Finland. Participant follow-up is still ongoing. DNA, serum and plasma available from 7300 participants, genotype data available from 7270 participants.
THL
A comprehensive combination of health interview and health examination survey carried out by THL in 2000-2001 with a follow-up in 2011. Investigating public health problems and population’s functional capacity in working-aged and the aged population in Finland. 8 611 individual participants, DNA, serum and plasma available from all participants (baseline and follow-up), genotype data available from 7700, WES 4960 , WGS 205 NMR metabolomics 10290, Telomers 7404
Helsinki BB
Five-year trial, collected between 1981-90, testing the efficacy of simultaneously elevating serum levels of HDL cholesterol and lowering levels of non-HDL cholesterol with gemfibrozil in reducing the risk of coronary heart disease in asymptomatic men. Blood/DNA and serum available from 4000 participants, genotype data currently available from 2000 participants.
Helsinki BB
Studying incidence, risk factors and outcome of acute kidney injury (AKI) in Finnish Intensive Care Units. 2546 participants. DNA/genotype data available from all participants.
THL
THL
The Migraine Family Study by FIMM/UH is focused on identifying variation in genes that are associated with migraine, headache-related symptoms and chronic disease risk factors. Collected since 1992 and ongoing. DNA available from 9450 participants, genotype data available from 8470 participants, WES 490, WGS 625.
Arctic Biobank
The University of Oulu has collected several extensive population survey data sets, such as the Northern Finland Birth Cohorts NFBC1966 and NFBC1986. Blood/DNA samples available from 14 400 participants, genotype data from 10 000 participants.
THL
The Alpha-Tocopherol, Beta-Carotene (ATBC) Lung Cancer Prevention Study (1984-1993) of male smokers was a randomized, double-blinded, placebo-controlled trial testing whether alpha-tocopherol and/or beta-carotene supplements can reduce the incidence of lung and other cancers. Serum 29 000, DNA samples available from 20 000 participants, genotype data from 4000.
THL
The Study is a part of the International Stanley Global Neuropsychiatric Genomics Initiative, seeking to expand knowledge of genetic diversity and biological background in schizophrenia, bipolar disorder, and autism. DNA, serum and plasma available from 9350 and genotype data from 9025 participants.
THL
THL has collected samples and data from diabetics and their family members in several sub-studies between 1986 and 2013. The focus has been on the genetic background and environmental triggers of diabetes in Finland. Size: DNA from 13 600 participants, plasma, serum and cell samples from subsets; genotype data available from 9080 participants.
THL
The THL Psychiatric Family Collections include families ascertained for schizophrenia, schizoaffective disorder and bipolar spectrum disorder. The objective of the study is to identify the genetic risk factors for serious psychiatric disorders in Finnish families.
THL
Population-based study of UH collected from Finnish twins and their family members. Based on three longitudinal questionnaire data-sets from >14 000 participants. The collection has been expanded with follow-up sub-studies involving samples and data. DNA available from 14200 participants, genotype data available from 14100 participants.
FinnGen Legacy cohorts and chips
DS1_BOTNIA_Dgi
Affymetrix_250KNsp_250KSty
DS2_BOTNIA_T2dgo
lllumina_HumanOmni2.5-4v1_B_SNV_array
DS3_COROGENE_Sanger
Illumina Human610-Quadv1_B
DS4_FINRISK_Corogene
Human610-Quadv1_B
DS5_FINRISK_Engage
HumanCoreExome-12v1-0_A
DS6_FINRISK_FR02_Broad
GSAMD-24v1-0_20011747_A1
DS7_FINRISK_FR12
Illumina_HumanCoreExome-24-v1.1
DS8_FINRISK_Finpcga
Illumina_HumanCoreExome-12v1.1a
DS9_FINRISK_Mrpred
Illumina_HumanCoreExome-24_v1.0
DS10_FINRISK_Palotie
HumanCoreExome-12v1-1_A
DS11_FINRISK_PredictCVD_COROGENE_Tarto
HumanOmniExpress-12v1_A
DS12_FINRISK_Summit
HumanOmniExpress-12v1_H
DS13_FINRISK_Bf
Illumina_HumanCoreExome-24_v1.0
DS14_GENERISK
lllumina_HumanCoreExome-24v1-0_A
DS15_H2000_Broad
Broad_GWAS_supplemental_15061359_A1
DS16_H2000_Fimm
Illumina_HumanCoreExome-24v1-1_A
DS17_H2000_Genmets
Human610-Quadv1_B
DS18_MIGRAINE_1
PsychChip_15048346_B-_24
DS19_MIGRAINE_2
HumanCoreExome-12v1-0_A
DS20_SUPER_1
GSAMD-24v1-0_20011747_A1
DS21_SUPER_2
GSAMD-24v1-0_20011747_A1
DS22_TWINS_1
Illumina Human670/Human610
DS23_TWINS_2
IlluminaCoreExome
DS24_SUPER_3
GSAMD-24v1-0_20011747_A1
DS25_BOTNIA_Regeneron
GSA-24v1-0_A1
DS26_DIREVA
InfiniumCoreExome-24v1-1
DS27_NFBC66
Illumina HumanCNV370DUO Analysis BeadChip
DS28_NFBC86
HumanOmniExpressExome v 1.2
Last updated
Was this helpful?